Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575057 | 0.78 | TAAR1 (0.50) | TAAR1IDO1AOC3LMNAALDH1A1 | |
| SCHEMBL12473708 | 0.78 | TAAR1 (0.50) | TAAR1IDO1AOC3LMNAALDH1A1 | |
| SCHEMBL11456607 | 0.77 | TAAR1 (0.56) | TAAR1IDO1AOC3LMNAALDH1A1 | |
| SCHEMBL12954591 | 0.77 | TAAR1 (0.56) | TAAR1IDO1AOC3LMNAALDH1A1 | |
| SCHEMBL248425 | 0.76 | TAAR1 (0.48) | TAAR1IDO1AOC3LMNAALDH1A1 | |
| SCHEMBL30079047 | 0.76 | TAAR1 (0.48) | TAAR1IDO1AOC3LMNAALDH1A1 | |
| SCHEMBL21633667 | 0.76 | TAAR1 (0.48) | TAAR1IDO1AOC3LMNAALDH1A1 | |
| SCHEMBL3634562 | 0.76 | TAAR1 (0.48) | TAAR1IDO1AOC3LMNAALDH1A1 | |
| SCHEMBL28748396 | 0.76 | TAAR1 (0.48) | TAAR1IDO1AOC3LMNAALDH1A1 | |
| SCHEMBL168715 | 0.76 | TAAR1 (0.48) | TAAR1IDO1AOC3LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744127-B2 | MDR-reversing 8-hydroxy-quinoline derivatives | MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) | 2020-08-18 | — | — | US | claimed |
| US-20190151306-A1 | MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES | MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) | 2019-05-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151306-A1 | MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES | ABCC1, ABCB1, ABCC8 | TAAR1 4554/4885IDO1 3317/4885AOC3 4742/4885 |
| US-10744127-B2 | MDR-reversing 8-hydroxy-quinoline derivatives | ABCC1, ABCB1, ABCC8 | TAAR1 4554/4885IDO1 3317/4885AOC3 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.